IDEAYA Biosciences (IDYA) News Today $42.39 +0.10 (+0.24%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 7:29 AM | marketbeat.comQ3 2024 Earnings Estimate for IDEAYA Biosciences, Inc. Issued By Leerink Partnrs (NASDAQ:IDYA)IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2024 earnings estimates for shares of IDEAYA Biosciences in a note issued to investors on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now anticipates that the company will pJuly 23 at 7:49 AM | marketbeat.com32,610 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Bought by Orion Portfolio Solutions LLCOrion Portfolio Solutions LLC acquired a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 32,610 shares of the company's sJuly 22, 2024 | americanbankingnews.comAnalysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $52.92July 21, 2024 | marketbeat.comSwiss National Bank Boosts Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Swiss National Bank boosted its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 30.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,400 shares of the company's stock afJuly 21, 2024 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Trading 2.7% Higher July 20, 2024 | marketbeat.comMarketBeat Week in Review – 7/15 - 7/19 (IDYA)Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves nextJuly 19, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Up 2.7%IDEAYA Biosciences (NASDAQ:IDYA) Shares Up 2.7%July 19, 2024 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $41.35July 19, 2024 | americanbankingnews.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Sees Significant Increase in Short InterestJuly 19, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Issued By WedbushJuly 19, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Buy" from BrokeragesIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has earned a consensus rating of "Buy" from the fourteen analysts that are covering the company, Marketbeat Ratings reports. Fourteen analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have isJuly 18, 2024 | marketbeat.comEntropy Technologies LP Acquires New Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Entropy Technologies LP acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 15,473 shares of the company's stock, valued at approximately $679,000. OthJuly 18, 2024 | marketbeat.comWedbush Comments on IDEAYA Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:IDYA)IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Equities research analysts at Wedbush lifted their Q2 2024 earnings per share estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, July 16th. Wedbush analyst R. Driscoll now expects that the company will post eJuly 18, 2024 | americanbankingnews.comWedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)July 16, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Receives "Outperform" Rating from WedbushWedbush restated an "outperform" rating and issued a $54.00 target price (down from $56.00) on shares of IDEAYA Biosciences in a report on Tuesday.July 15, 2024 | marketbeat.comPositive News is Driving This Cancer Drug Maker's Stock HigherShares of IDEAYA Biosciences Inc. NASDAQ: IDYA are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company's pipeline candidate, IDE397, is an experimental drug designed to treat certain bladder and small-cell lung cancers.July 15, 2024 | marketbeat.comPositive News is Driving This Cancer Drug Maker’s Stock Higher (IDYA)IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breatherJuly 12, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $69.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their target price on shares of IDEAYA Biosciences from $65.00 to $69.00 and gave the stock an "overweight" rating in a research report on Friday.July 12, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets lowered its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 40.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 123,015 shares of the companJuly 11, 2024 | prnewswire.comIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesJuly 11, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) PT Raised to $61.00 at Royal Bank of CanadaRoyal Bank of Canada lifted their price target on shares of IDEAYA Biosciences from $53.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday.July 11, 2024 | marketbeat.comResearch Analysts Issue Forecasts for IDEAYA Biosciences, Inc.'s FY2027 Earnings (NASDAQ:IDYA)IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Stock analysts at Wedbush lowered their FY2027 earnings estimates for shares of IDEAYA Biosciences in a report issued on Monday, July 8th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.58) foJuly 10, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Down to $38.62IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Down to $38.62July 9, 2024 | prnewswire.comIDEAYA Announces Pricing of Public OfferingJuly 9, 2024 | prnewswire.comIDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJuly 9, 2024 | marketbeat.comJennison Associates LLC Acquires Shares of 256,249 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Jennison Associates LLC acquired a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 256,249 shares of the company's stock, valJuly 9, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Given New $62.00 Price Target at BTIG ResearchBTIG Research increased their price target on IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday.July 9, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Up 3.7% on Analyst UpgradeIDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 3.7% Following Analyst UpgradeJuly 8, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) PT Raised to $60.00Oppenheimer raised their price target on shares of IDEAYA Biosciences from $53.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday.July 8, 2024 | marketbeat.comIDEAYA Biosciences' (IDYA) Buy Rating Reaffirmed at Stifel NicolausStifel Nicolaus reiterated a "buy" rating and issued a $63.00 price target on shares of IDEAYA Biosciences in a research note on Monday.July 8, 2024 | investopedia.comIDEAYA Biosciences Soars on Cancer Drug Study ResultsJuly 8, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $34.26IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $34.26July 8, 2024 | seekingalpha.comIdeaya Biosciences: Poised For Success In Bladder And Lung Cancer?July 8, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Earns Outperform Rating from Analysts at MizuhoMizuho began coverage on IDEAYA Biosciences in a research note on Monday. They issued an "outperform" rating and a $50.00 price target on the stock.July 8, 2024 | prnewswire.comIDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung CancerJuly 6, 2024 | marketbeat.comVanguard Group Inc. Has $123.67 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Vanguard Group Inc. lifted its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 17.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,475,772 shares of theJuly 5, 2024 | prnewswire.comIDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024July 2, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 5.1%IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 5.1%July 1, 2024 | marketbeat.comWellington Management Group LLP Makes New Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Wellington Management Group LLP bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 83,984 shares of the company's stock, valued at apJune 28, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 25, 2024 | prnewswire.comIDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder CancerJune 24, 2024 | prnewswire.comIDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid TumorsJune 24, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Buy" from BrokeragesIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has earned an average rating of "Buy" from the thirteen analysts that are currently covering the company, Marketbeat reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 12-month price target amongJune 19, 2024 | marketbeat.comFisher Asset Management LLC Has $19.20 Million Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Fisher Asset Management LLC grew its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 1,611.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 539,676 shares of the company's stock after buying an additional 508,151 shares during the period. FJune 18, 2024 | seekingalpha.comIdeaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'June 14, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stake Boosted by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 17.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,566,278 shares of tJune 13, 2024 | marketbeat.comBoone Capital Management LLC Reduces Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Boone Capital Management LLC lessened its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 6.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 531,967 shares of the company's stock after selling 38,715 shares durJune 12, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $37.58IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $37.58June 12, 2024 | marketbeat.comFirst Light Asset Management LLC Purchases New Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)First Light Asset Management LLC acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 345,674 shares of the company's stock, valued at approximateJune 11, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stake Reduced by Avidity Partners Management LPAvidity Partners Management LP cut its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,520,000 shares of the comp Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address This TSLA short trade is on a nine win hot streak (Ad)Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself. But I can promise that you’ll see all the details for yourself here. IDYA Media Mentions By Week IDYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼0.980.62▲Average Medical News Sentiment IDYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼94▲IDYA Articles Average Week Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Catalyst Pharmaceuticals News Syros Pharmaceuticals News Cue Biopharma News TherapeuticsMD News Insmed News Legend Biotech News Catalent News Intra-Cellular Therapies News Roivant Sciences News Cerevel Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
